comparemela.com

Latest Breaking News On - Provider selection - Page 3 : comparemela.com

Global Phase I CRO (Clinical Research Organization) Benchmarking Report 2021: Many Sponsor Companies Turn to CROs for the Heavy Lifting of Their Clinical Development Programs

World Bioprocessing Market Report 2020-2025: Competitive Landscape Via Sponsor Awareness, Consideration, Use and Preference Rates for the 40 Included CMOs

Share this article Share this article ResearchAndMarkets.com s offering. The Bioprocessing Market Trends and Outsourcing Dynamics: 2020-2025 provides an overview of the current market dynamics for bioprocessing as well as a prediction of what the marketplace will look like in five years. Biologics have transformed the practice of medicine in a relatively short period of time because of their ability to treat complex diseases, various cancers and autoimmune disorders with fewer side effects than traditional small molecule medications. As a result, respondents predict significant biologics market growth in a variety of therapeutic categories. Key statistics include annual project volume, proportion outsourced, and number of CMOs to complete the work; use rates of the main production systems, the proportion of marketed biologics based off each development platform, which platforms are more likely to be outsourced, and a breakdown of annual outsourced expenditure by the platform.

Global Phase II/III Service Providers CRO Quality Benchmarking Report 2020: Service Provider Selection Process, Service Provider Perceptions and Interactions, Study Data, Demographics

Share this article Share this article ResearchAndMarkets.com s offering. Clinical outsourcing needs and perceptions can vary quite a bit by company. The publisher understands the desire for a deeper dive regarding the small and emerging biopharma landscape. This research will help small and emerging biopharma companies make more informed CRO selection decisions. These findings will also help CROs optimize operational and marketing strategies to better accommodate this segment. The degree of detail provided in this report - straight from small and emerging biopharma customers - on CRO awareness, familiarity, reported use, and preference along with perceived leadership, cost perceptions and CRO selection drivers offers a bird s eye view into this segment.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.